Ascitic fluid analysis in malignancy-related ascites.
A prospective study identified 45 patients with malignancy-related ascites among 448 ascites patients (10% of the total). Patients were categorized into five subgroups based on the pathophysiology of ascites formation. Each subgroup had a distinctive ascitic fluid analysis. Patients with peritoneal carcinomatosis but without massive liver metastases (53.3% of the patients with malignancy-related ascites) had a uniformly positive ascitic fluid cytology, high ascitic fluid protein concentration and low serum-ascites albumin gradient. Patients with massive liver metastases and no other cause for ascites formation (13.3% of the series) had a negative cytology, low ascitic fluid protein concentration, high serum-ascites albumin gradient and markedly elevated serum alkaline phosphatase. Those with peritoneal carcinomatosis and massive liver metastases (13.3% of the series) had a nearly uniformly positive ascitic fluid cytology, variable protein concentration, high serum-ascites albumin gradient and markedly elevated serum alkaline phosphatase. Chylous ascites (6.7%) was characterized by a milky appearance, negative cytology and an elevated ascitic fluid triglyceride concentration. Patients with hepatocellular carcinoma superimposed on cirrhosis (13.3%) had negative ascitic fluid cytology, low ascitic fluid protein concentration, high serum-ascites albumin gradient and elevated serum and ascitic fluid alpha-fetoprotein concentration. Two-thirds of patients with malignancy-related ascites had peritoneal carcinomatosis; 96.7% of patients with peritoneal carcinomatosis had positive ascitic fluid cytology. Ascitic fluid analysis is helpful in identifying and distinguishing the subgroups of malignancy-related ascites.
Runyon
B A
BA
Liver Unit, University of Southern California, Downey, California 90242.
Hoefs
J C
JC
Morgan
T R
TR
D000469:Alkaline Phosphatase / Q000097:blood; D001201:Ascites / Q000145:classification / Q000209:etiology / Q000503:physiopathology*; D001202:Ascitic Fluid / Q000032:analysis* / Q000166:cytology / Q000382:microbiology; D002915:Chylous Ascites / Q000145:classification / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D009363:Neoplasm Proteins / Q000032:analysis; D009369:Neoplasms / Q000032:analysis* / Q000150:complications; D010534:Peritoneal Neoplasms / Q000556:secondary; D011446:Prospective Studies; D012709:Serum Albumin / Q000032:analysis
D009363:Neoplasm Proteins; D012709:Serum Albumin; D000469:Alkaline Phosphatase